Vertical transmission is becoming the leading source of infection for those individuals, especially pregnant women who have never been tested for the presence of human immunodeficiency virus (HIV) or hepatitis C virus (HCV) in their blood.
According to CDC, almost one in six (15.8%) people in the U.S with this disease are unaware of their infection. HIV screening in pregnant women is crucial as an HIV infected mother can pass the virus to her baby during pregnancy, delivery or while breast-feeding. Testing for the presence of the virus in your blood is usually done by way of blood test. The first test used is the enzyme-linked immunosorbent assay (ELISA). It is a test to see whether your blood contains HIV antibodies. Prior to antiviral therapy, the risk of HIV transmission from an infected mother to her newborn was approximately 25%-35%.
Early detection of HIV can make treatment more effective and prevent transmission. The U.S. CDC has recommended HIV combination tests to detect the virus as well as specific antibodies in the blood up to three to four weeks faster. These HIV Combo tests are available with leading manufacturers such as Abbott Laboratories and Alere Inc.
HIV co-infection is found to be a factor to increase the risk of perinatal transmission of HCV. Similar to HIV, the CDC reports that the rising rates of hepatitis C infection is high among young, primarily white injection drug users, both male and female. The worldwide prevalence of hepatitis C virus (HCV) infection in pregnant women is estimated to be between 1% and 8%. Most children get this infection from their mothers at birth. Reliable HCV tests are available in the market. The DRG Hepatitis C Virus IgG Enzyme Immunoassay Kit provides materials for the qualitative and semi-quantitative determination of IgG-class antibodies to Hepatitis C Virus in serum. HCV Ab ELISA, 96 Wells is a third generation Enzyme ImmunoAssay (ELISA) to determine antibodies to Hepatitis C Virus in human plasma and serum.